TrialCancer discovery2013
Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas.
Alexander Drilon et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
229 papers cite itlatest 60 shown
this paperpooled ittrialcites it